Please login to the form below

Not currently logged in
Email:
Password:

LAL-D

This page shows the latest LAL-D news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy

However, its 2015 takeover of Synageva for $8.4bn has been less successful, with Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency (LAL-D) so far failing to deliver its expected ... The underperformance led Alexion into a restructuring drive

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics